著者

Yoshito MIYATA Shin OHTA Akihiko TANAKA Kaho AKIMOTO Hiroki SATO Tomoki UNO Haruna SATO Yoshitaka UCHIDA Megumi JINNO Kuniaki HIRAI Hideki INOUE Tetsuya HONMA Mayumi YAMAMOTO Shintaro SUZUKI Hironori SAGARA

出版者

The Showa University Society

雑誌

The Showa University Journal of Medical Sciences (ISSN:09156380)

巻号頁・発行日

vol.32, no.4, pp.247-256, 2020 (Released:2021-01-28)

参考文献数

28

---

Mepolizumab is a monoclonal antibody against interleukin-5 used for the treatment of severe asthma. The effect of long-term mepolizumab administration and its persistence in clinical practice is poorly understood. Thus, this study aimed to investigate the effect of long-term administration of mepolizumab in patients with severe asthma. Mepolizumab was administered to 20 patients with severe asthma. We then prospectively followed the patients for 104 weeks to investigate the efficacy of long-term mepolizumab administration in clinical practice. Eleven patients were evaluated for 104 weeks. Mepolizumab administration reduced asthma exacerbations in a year from 52 to 104 weeks and improved asthma control in every period as assessed by questionnaires. Also, blood eosinophil counts decreased at every point, and blood basophil counts decreased at 104 weeks. We compared various parameters among the 11 patients who continued administration for more than 104 weeks and 7 patients who discontinued treatment due to ineffectiveness. Significant differences were observed in disease duration, maximum expiratory flow at 50%, and blood basophil count. Long-term mepolizumab administration improved asthma symptoms in patients with severe asthma and reduced the frequency of exacerbations.